Drug development advances in human genetics‐based targets
X Zhang, W Yu, Y Li, A Wang, H Cao, Y Fu - MedComm, 2024 - Wiley Online Library
Drug development is a long and costly process, with a high degree of uncertainty from the
identification of a drug target to its market launch. Targeted drugs supported by human …
identification of a drug target to its market launch. Targeted drugs supported by human …
Hepatic steatosis and its associations with acute and chronic liver diseases
AB Koenig, A Tan, H Abdelaal, F Monge… - Alimentary …, 2024 - Wiley Online Library
Background Hepatic steatosis is a common finding in liver histopathology and the hallmark
of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non …
of metabolic dysfunction‐associated steatotic liver disease (MASLD), formerly known as non …
BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes
L Alcober-Boquet, N Kraus, LS Huber… - … of Physiology-Cell …, 2024 - journals.physiology.org
17-β-hydroxysteroid dehydrogenase 13 (HSD17B13), a lipid droplet-associated enzyme, is
primarily expressed in the liver and plays an important role in lipid metabolism. Targeted …
primarily expressed in the liver and plays an important role in lipid metabolism. Targeted …